Compare ADMA Biologics Inc (ADMA) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.5 (market cap $20.14M). The key difference: ADMA Biologics Inc is far larger — about 105.8× Avalanche Treasury Corporation Class A Common Stock's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ADMA | AVAT | |
|---|---|---|
Market Cap | $2.13B | $20.14M |
Sector | Health | Financials |
52-Week High | $20.38 | $10.75 |
52-Week Low | $7.60 | $0.51 |
Enterprise Value | $2.20B | $20.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AVAT trades at $0.5114, down 3.22% today, with a bearish technical signal from moving averages and a neutral oscillator reading. The company reported a net income of $8.28 million for 2025 but shows negative operating cash flow of -$930,710. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is cautious due to weak cash flow and bearish technicals, though low P/E and P/B ratios may appeal to value investors. Key risks include operational sustainability and market sentiment shifts. Analyst consensus is not yet established post-listing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
